Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that Ascent Health, the second largest Payer organisation in the US, will cover Sofdra (sofpironium) topical gel, 12.45 per cent.
Botanix expands US payer coverage for Sofdra with Ascent Health agreement
November 14, 2024 Australian Biotech
Latest Video
New Stories
-
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech -
PYC Therapeutics to progress polycystic kidney disease trial
July 7, 2025 - - Australian Biotech -
Pharmac minister prepares to deliver letter of expectations
July 7, 2025 - - Latest News -
UK's ten-year plan backs faster access, but industry laments lack of investment
July 7, 2025 - - Latest News